Immunic Inc. (IMUX) PT Raised to $61 at BMO Capital, Following Drug Trial Results
Tweet
Share
E-mailGet Alerts IMUX Hot Sheet
Price: $15.07 +2.17%
Rating Summary:
16 Buy, 1 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 14 | New: 26
Rating Summary:
16 Buy, 1 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 7 | Down: 14 | New: 26
Join SI Premium – FREE
BMO Capital analyst George Farmer raised the price target on Immunic Inc. (NASDAQ: IMUX) to $61.00 (from $40.00) while maintaining a Market Perform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Natera (NTRA) PT Raised to $270 at BTIG
- United Airlines (UAL) PT Raised to $153 at UBS Ahead of Q2 Results
- Alaska Air (ALK) PT Raised to $62 at UBS on Updated Q2 Estimates
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
